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Introduction
Patients with schizophrenia have been shown to behave differ-
ently to controls on tasks involving probabilistic decision making, 
with patients tending towards a ‘jumping to conclusions’ (JTC) 
style of reasoning (Garety et al., 1991; Huq et al., 1988; Moritz 
and Woodward, 2005; Mortimer et al., 1996). Typically this has 
been demonstrated using the ‘urn’ or ‘beads’ task, first proposed 
by Phillips and Edwards (1966). This simple task involves two 
containers (‘urns’) containing a large number of different col-
oured beads in differing ratios. One urn might contain 85% blue 
beads and 15% red beads, the other 85% red beads and 15% blue 
beads; the participant is informed of these proportions, although 
the containers are hidden from view. The experimenter then pre-
sents a series of beads one at a time to the participant, apparently 
having chosen one of the urns to draw from (but actually present-
ing a pre-prepared sequence of beads). After the participant is 
shown each bead they are asked if they want to guess which urn 
the beads are being drawn from, or see another bead. Huq et al. 
(1988) showed that deluded patients with schizophrenia required 
fewer draws before claiming to know which urn had been chosen, 
compared with controls. This tendency to accept hypotheses pre-
maturely has been proposed to be critical in encouraging delusion 
formation by contributing to erroneous inferences (Garety, 1991). 
JTC can be detected reliably in delusional individuals (Fine et al., 
2007). However, JTC also appears to be present in patients with 
schizophrenia independent of whether delusions are present. 
Many early studies did not include a non-deluded schizophrenia 
group as a control, but recent studies have shown similar levels of 
JTC in both deluded and non-deluded patients using the beads 
task (Menon et al., 2006; Moritz and Woodward, 2005; Mortimer 
et al., 1996). Peters and Garety (2006) tested patients twice, once 
when actively deluded, and then again when in remission. The 
JTC bias was found to be stable. Similarly, successful antipsy-
chotic treatment is not associated with a reduction in JTC (Menon 
et al., 2008). This indicates that JTC might be a trait marker for 
schizophrenia. Consistent with this, Van Dael et al. (2006) found 
evidence of a JTC response pattern in first-degree relatives of 
patients with schizophrenia. There is also evidence of a JTC ten-
dency in prodromal groups (Broome et al., 2007).
Recently, there has been considerable interest in the non- 
competitive NMDA receptor antagonist ketamine as a potential model 
for schizophrenia. Ketamine infusions in healthy participants have been 
shown to result in behavioural and cognitive disturbances that are con-
sistent with schizophrenic symptoms (Adler et al., 1999; Krystal et al., 
1994; Malhotra et al., 1996). Furthermore, ketamine reliably exacerbates 
symptoms in patients with schizophrenia, with patients tending to report 
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a re-activation of individual psychotic symptoms under ketamine (Lahti 
et al., 1995, 2001; Malhotra et al., 1997). Furthermore, glutamate recep-
tor agonists demonstrate therapeutic efficacy (Patil et al., 2007), although 
evidence of glutamatergic receptor dysfunction in schizophrenia as 
shown by post-mortem studies is equivocal (McKenna, 2010). Healthy 
controls receiving ketamine tend not to report the auditory hallucinations 
often present in schizophrenia, but ketamine reliably induces many nega-
tive symptoms including emotional flattening, loss of verbal fluency and 
impaired memory (Adler et al., 1998; Lahti et al., 2001; Newcomer and 
Krystal, 2001). Not all negative symptoms are replicated, since ketamine 
rarely reproduces the disorganized thinking and speech characteristic of 
schizophrenia, at least not at the doses normally employed by research 
studies (Lahti et al., 2001; Newcomer and Krystal, 2001). Sensitivity to 
ketamine varies considerably between individuals. Interestingly, base-
line brain activity has been shown to predict vulnerability to ketamine-
induced psychosis, and these predictive relations are consistent with 
symptom-related pathophysiology in schizophrenia (Honey et al., 2008). 
However, delusional thinking has been reliably reported under ketamine 
(Corlett et al., 2006; Pomarol-Clotet et al., 2006). A recent study examin-
ing recreational ketamine use found increased delusional symptoms in 
frequent, infrequent, and ex-users, with symptomatology correlating 
positively with the level of ketamine abuse (Morgan et al., 2009).
Certain prominent theories of delusion formation implicate 
disrupted processing of reward or error signals (Gray and 
Snowden, 2005; Hemsley, 2005; Kapur, 2003, 2004; Kapur et al., 
2005) and since ketamine has been shown to impact both gluta-
matergic and dopaminergic systems (Kapur and Seeman, 2002; 
Moghaddam et al., 1997) this provides a plausible mechanism for 
delusion formation under ketamine. Specifically, ketamine infu-
sion can lead to enhanced dopamine release in the striatum (Breier 
et al., 1998; Vollenweider et al., 2000) and dopamine signalling is 
assumed to represent prediction error and therefore drive associa-
tive learning (Schultz, 2002). Furthermore, prediction error 
responses in lateral prefrontal cortex (PFC) are disrupted by low-
dose ketamine such that, under ketamine, PFC activity no longer 
distinguishes between predicted and unpredicted occurrences 
(Corlett et al., 2006). Prefrontal responses to mesolimbic input are 
influenced by glutamate (Lavin et al., 2005), and antagonism of 
NMDA receptors by ketamine could result in disinhibition of glu-
tamatergic neurons (Moghaddam et al., 1997). Thus, misattribu-
tions of reward value under ketamine could lead to certain stimuli 
becoming highly salient, leading to an early decision and the pre-
mature acceptance of a hypothesis, which could result in delu-
sions. Ketamine effects on neural reward circuitry could therefore 
explain the prevalence of delusional thinking under ketamine.
In the present study, our aim was to investigate how acute keta-
mine affects performance on the urn task in healthy controls. 
Since patients have been shown to make early decisions on the urn 
task, and acute ketamine can induce symptomatology consistent 
with schizophrenia, we hypothesized that ketamine would lead to 
a JTC response style in healthy controls. Each participant received 
two different doses of ketamine plus a placebo condition, and per-
formance on the urn task was tested under each condition. 
Furthermore, to assess performance under ketamine in relation to 
its proposed role as a model for schizophrenia, a group of patients 
was also tested on an identical urn task. A control group not under-
going ketamine infusion (age and IQ-matched to the patients with 
schizophrenia) was also recruited. By comparing performance 
between patients and their controls and healthy participants 
receiving ketamine or placebo, we tested whether ketamine could 
induce the JTC performance pattern typically observed in patients.
Methods
Ketamine group
Participants and design. Participants were recruited through 
an advertisement and were paid for their participation. The study 
was performed in accordance with the declaration of Helsinki and 
was approved by the institutional ethics committee (the UCL/
UCLH Committee on the Ethics of Human Research). All partici-
pants gave written, witnessed, informed consent. The inclusion 
criteria were that participants were between 18 and 35 years old, 
with no general health problems and on no regular medications. In 
all, 20 healthy volunteers (14 male) responded to the advertise-
ment and all took part in this study. Of these, two participants 
dropped out due to adverse effects: one had a vasovagal episode 
immediately after intravenous cannulation and one participant 
vomited after ketamine administration and thus could not con-
tinue with testing. Two further participants withdrew midway 
through the study and their data were excluded from analysis.
Each participant was administered three different ketamine tar-
get controlled infusions (see flow chart, Figure 1). These doses were 
administered on three separate occasions, a minimum of 1 week 
apart. Participants received the doses in a randomized order; rand-
omization was carried out by the clinical team. Double-blinded pro-
cedures were used throughout; only the clinician knew the target 
dose administered. The procedure was identical regardless of 
whether ketamine or placebo was delivered, and the researcher 
administering the task (SE) did not know the dose. Thus all partici-
pants underwent testing at each dose of ketamine. Groups were not 
balanced for gender since more men were recruited. In total, 16 par-
ticipants completed the study (mean age 25.5 years, SD = 3 years).
Drug administration. A 22 gauge intravenous cannula was 
inserted in the dorsum of the participant’s hand and a ketamine infu-
sion was commenced via a Graseby 3400 intravenous infusion 
pump controlled by the Stanpump program (Shafer et al., 1990). 
The program uses a ‘BET’ (bolus–elimination–transfer) infusion 
scheme that aims to achieve the target plasma concentration almost 
instantaneously by taking into account ketamine pharmacokinetics 
using a three-compartment model (Domino et al., 1984). The clini-
cal team employed a similar protocol in a previous research study 
(Stefanovic et al., 2009). Participants received ketamine aiming for 
effect-site plasma concentrations of 150 ng/mL, 100 ng/mL and pla-
cebo (0.9% NaCl). After behavioural testing was complete a venous 
blood sample was taken from the antecubital fossa of the other arm 
to the ketamine infusion. Plasma was obtained immediately from 
Figure 1. Flow chart depicting test procedure.
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blood samples by centrifugation and samples were stored at -80°C. 
Ketamine levels were assessed by C3P Analysis (Plymouth, UK). 
This showed that ketamine levels tended to be in excess of target 
(Figure 2). t-tests confirmed that ketamine plasma levels differed 
significantly from one another (all pair-wise t-tests, p < 0.001).
Procedure. Testing occurred between 14:00 and 18:00 and the 
time of testing was broadly matched across groups. Participants 
arrived at the hospital after completing a 6-h fast.
The anaesthetist commenced the infusion after intravenous 
cannulation. Throughout the infusion, the participant’s pulse, 
blood pressure, oxygen saturation and electrocardiogram (ECG) 
were monitored. At the end of each session, participants were 
assessed by medical staff as to their ‘street readiness’. Participants 
were given a contact telephone number for the clinical team in 
case of adverse effects after departure; none were reported.
Patient group
We recruited 39 individuals who met the DSM-IV criteria for 
schizophrenia from the outpatient department of South London 
and Maudsley NHS Trust. Patients were stable on treatment with 
antipsychotic medication (Table 1), those with dual diagnoses and 
drug and alcohol problems were excluded from the study. Patients 
underwent a Positive and Negative Syndrome Scale (PANSS) 
diagnostic interview on the day of testing; demographic details 
and PANSS scores are given in Table 1.
Patient control group
Some 39 control participants were also recruited, and these were 
age and IQ matched to the patient group. Inclusion criteria stipu-
lated no psychiatric history and no history of drug/alcohol prob-
lems. For demographic information see Table 1.
Task
All groups received the same test materials, which were delivered 
via computer. For the ketamine group, testing commenced once 
the clinician was satisfied that the dose levels had stabilized. All 
groups received the same instructions, on-screen, prior to testing. 
The task followed the standard procedure for the ‘urn’ task (Huq 
et al., 1988). Participants were told that they would be shown 
beads from two ‘urns’ containing blue and red beads in a 85/15 
and 15/85 ratio. After each bead was drawn and shown to the par-
ticipant, the participant indicated whether they wanted to draw 
again, or guess the urn. During the task, for each sequence, a 
series of beads (represented by coloured discs on-screen) was pre-
sented to the participant. The participant used the keyboard after 
every presentation to indicate whether (a) s/he would like to be 
shown another bead or (b) make a decision as to the ‘urn’, and if 
so, which ‘urn’ to choose. Only the last bead was shown on the 
screen. The series of presentation was pre-determined. Five differ-
ent sequences were presented. Sequence order was randomized 
both within (i.e. across sessions) and between subjects. The 
sequences were:
Sequence 1: [R R R R R R R R R R]
Sequence 2: [R B R R R R R R R R]
Sequence 3: [B B R B B B B B B B]
Sequence 4: [R B B B B B B B B B]
Sequence 5: [B B R R R R R R R R]
In the ketamine group, participants completed the task on each 
of the three test days. In the patient, and patient control groups, 
Figure 2. Mean ketamine levels in blood plasma according to target dose.
Table 1. Participant demographic information.
Patient group (n = 39, Male = 30) Control group (n = 39, Male = 26) Ketamine group (n = 16, Male = 12)
 Mean (s.d.) Range Mean (s.d.) Range Mean (s.d.) Range
Age 38.84 (9.35) 21–61 34.24 (13.23) 18–61 25.5 (3) 24–34
IQ 104.9 (11.8) 81–128 112.2 (13.0) 75–127  
PANSS score
Positive 13.89 (6.03) 7–26  
Negative 13.81 (6.09) 7–34  
Total 52.45 (15.58) 30–89  
Medication
Chlorpromazine  
Equivalents (mg/day)
325 (225)* 100–1000  
*These data were unavailable for five of the participants.
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participants were tested once (see flow chart, Figure 1). In the 
ketamine group, participants were cannulated on all of the test 
days. Patients and patient controls were not cannulated on their 
test day.
Data analysis
In line with previous work employing this task, the dependent 
variable was ‘draws to decision’; we calculated the average num-
ber of beads shown per sequence before a decision was made. 
This applied to all groups of participants. For the ketamine group, 
a one-way analysis of variance (ANOVA) with random effects 
was employed to test the hypothesis that dose level as a within-
subject factor had a significant effect on mean draws to decision. 
A one-way ANOVA was also used to test for a difference between 
patients and matched control groups, except in this case the group 
effect was between subject. Data from patients, matched controls, 
placebo and high dose ketamine were then entered into a single 
one-way ANOVA. In this case, the ketamine dose was not treated 
as a repeated measure but rather as a between-subject factor. A 
contrast was specified over these four groups to compare differ-
ences between patients and controls with differences between pla-
cebo and high dose ketamine. SPSS was used for all analyses.
Results
The initial analysis examined within-subjects data in the ketamine 
group, and a between-subjects comparison between the patients 
and matched controls.
For the ketamine group, an ANOVA on the mean number of 
draws showed no effect of ketamine dose (F(2,45) = 0.08, 
p = 0.92). Thus, participants made approximately the same num-
ber of draws under each dose of ketamine (Figure 3). When the 
same analysis was carried out on the patients and their matched 
controls, we found a significant main effect of group (F (1,76) = 
18.64, p < 0.001). Similar to previous studies, patients required 
fewer draws before they inferred the urn than controls (Figure 4).
Subsequent to this, an additional ANOVA was used to compare 
data from four groups. Data from patients, matched controls, keta-
mine group (placebo) and ketamine group (high dose) were entered 
into a single one-way ANOVA. It was found that performance dif-
ferences between patients and their matched controls were larger 
than the difference between participants receiving ketamine (150 
ng/mL) and placebo. A contrast was specified which tested the 
value of (patients - controls) - (high dose - placebo). This contrast 
was found to be significant (t (106) = 2.187, p = 0.031). Thus, the 
differences between each pair of groups (as specified in the con-
trast) were themselves different from each other.
Discussion
Previous studies have shown that ketamine can model some 
aspects of schizophrenic symptomatology (Adler et al., 1999; 
Krystal et al., 1994; Malhotra et al., 1996). Other work has shown, 
reliably, that patients with schizophrenia show a JTC reasoning 
bias in probabilistic inference tasks (Averbeck et al., 2011; Garety 
and Freeman, 1999; Huq et al., 1988). Deluded patients show this 
bias even when a memory aid is included in the ‘urn’ task, sug-
gesting that memory difficulties are not responsible (Dudley et al., 
1997). While we were able to replicate the JTC bias in patients 
relative to matched controls, we found no evidence that ketamine 
made healthy controls adopt a JTC reasoning bias. It could be 
argued that the dosages employed here were insufficient since 
some previous studies (which reported high levels of delusional 
ideation) used a higher dose of 200 ng/mL (Corlett et al., 2006; 
Pomarol-Clotet et al., 2006). However, we found that our actual 
blood levels were significantly higher than the target, in some 
Figure 3. Probability distributions of ‘draws to decision’ under ketamine. Pooled data across all participants, according to dose.
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cases exceeding 200 ng/mL. Therefore, we do not believe that 
insufficient ketamine levels can account for lack of an effect. We 
adopted a lower target dose because pilot testing at higher doses 
led us to believe that the level of drop-out would be high; further-
more, at 200 ng/mL target dose, our pilot participant was physi-
cally unable to perform the task.
Ketamine has been shown to promote delusions and other ‘pos-
itive’ symptoms in healthy controls (Corlett et al., 2006; Pomarol-
Clotet et al., 2006), and worsen the psychotic symptoms of patients 
(Lahti et al., 1995, 2001; Malhotra et al., 1997). Some theories of 
delusion formation have related JTC to disruptions in either reward 
(Kapur, 2003, 2004; Kapur et al., 2005) or prediction error (Gray, 
1995) signals, and ketamine has been shown to influence these 
signals (Corlett et al., 2006; Vollenweider et al., 2000). 
Nevertheless, we have found that performance on the urn task is 
not affected by ketamine, suggesting that perhaps JTC does not 
result directly from abnormal dopaminergic or glutamatergic sig-
nalling. This ties in with behavioural studies comparing responses 
in the urn task with other probabilistic inference tasks, showing 
that patients who jump to conclusions actually learn less from 
rewarding stimuli than patients who gather more information 
(Averbeck et al., 2011). This does not support an increased sali-
ence or increased reward prediction error hypothesis of JTC, 
instead suggesting a decreased threshold for making inferences. 
This does not imply simple impulsivity, however, since patients 
adjust their behaviour if task difficulty is increased, requiring more 
draws to decision (Dudley et al., 1997). It is possible that increased 
tonic dopamine levels in patients with schizophrenia are driving 
them to respond quickly, and that ketamine does not increase tonic 
dopamine levels. This, however, remains an open question.
The results of the current study suggest that ketamine infusion 
does not replicate in controls the JTC tendency observed in patients. 
Ketamine certainly does not induce all aspects of schizophrenia 
symptomatology, since certain negative symptoms in particular are 
largely absent; nevertheless, ketamine tends to provoke a wider 
range of psychotic symptoms compared with amphetamine (Lahti 
et al., 2001). However, although ketamine delivery does exacerbate 
psychotic symptoms in patients, there are qualitative differences in 
ketamine effects between patients and controls (Malhotra et al., 
1997). The data reported here suggest that the JTC aspect of schizo-
phrenic cognition is not reproduced by ketamine, and raises the 
possibility that delusion formation under ketamine is not under-
pinned by JTC. Nevertheless, certain important caveats should be 
noted. The urn task employed here explores one specific case of 
probabilistic inference. Therefore the results reported here do not 
imply that ketamine has no effect on probabilistic inferences, since 
a more comprehensive investigation is required. Disruptions to 
fronto-striatal activity caused by ketamine might not be sufficient 
to alter behaviour in the urn task. A more sensitive measure may be 
required. Although a JTC style of reasoning has been demonstrated 
in patients using other tasks (Kemp et al., 1997; Linney et al., 
1998), it seems that the task structure might be critical. Specifically, 
it has been suggested that stress induced by perceived time pressure 
in the urn task might cause patients with schizophrenia to appraise 
stimuli inaccurately (Glöckner and Moritz, 2009), although this 
needs to be more fully explored. Also, studies of executive function 
under ketamine point to task-specific impairments (Honey et al., 
2003; Krystal et al., 2000), raising the possibility that participants 
altered their cognitive strategy to perform as normal on the urn task 
under ketamine. Further work employing more challenging proba-
bilistic inference tasks would be useful for exploring these possi-
bilities. One could, for example, increase the difficulty of the urn 
task (since JTC might manifest only under certain levels of task 
difficulty) or use a more in-depth assessment tool such as Mouselab 
(Payne et al., 1988) to investigate decision strategies. In addition, a 
recent study has shown that certain cognitive changes relating to 
delusion proneness are only detectable following chronic adminis-
tration of ketamine (Freeman et al., 2009). Although recruitment of 
recreational drug users presents certain difficulties (since most are 
polydrug users, for example), this might provide a worthwhile 
insight into the cognitive changes induced by ketamine use.
Conclusion
We have found that acute administration of the NMDA antagonist 
ketamine does not appear to replicate in controls the JTC response 
pattern frequently observed in patients with schizophrenia. Further 
work using other probabilistic inference tasks would be 
Figure 4. Probability distributions of ‘draws to decision’ for patients, matched controls, and controls receiving ketamine at the higher dose.
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beneficial, as would investigations in chronic ketamine users. The 
characterization of reasoning biases in patients receiving keta-
mine would also be informative.
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